These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis. Angeles-Han ST; Lo MS; Henderson LA; Lerman MA; Abramson L; Cooper AM; Parsa MF; Zemel LS; Ronis T; Beukelman T; Cox E; Sen HN; Holland GN; Brunner HI; Lasky A; Rabinovich CE; Arthritis Care Res (Hoboken); 2019 Apr; 71(4):482-491. PubMed ID: 29806733 [TBL] [Abstract][Full Text] [Related]
7. Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis. Horneff G; Klein A; Ganser G; Sailer-Höck M; Günther A; Foeldvari I; Weller-Heinemann F Pediatr Rheumatol Online J; 2017 Nov; 15(1):78. PubMed ID: 29116003 [TBL] [Abstract][Full Text] [Related]
8. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Ter Haar NM; van Dijkhuizen EHP; Swart JF; van Royen-Kerkhof A; El Idrissi A; Leek AP; de Jager W; de Groot MCH; Haitjema S; Holzinger D; Foell D; van Loosdregt J; Wulffraat NM; de Roock S; Vastert SJ Arthritis Rheumatol; 2019 Jul; 71(7):1163-1173. PubMed ID: 30848528 [TBL] [Abstract][Full Text] [Related]
9. Implementation study of the CARRA Uveitis Consensus Treatment Plans: feasibility for clinical practice and applicability for research. Chang MH; Barbar-Smiley F; Akoghlanian S; Drew J; Angeles-Han ST; Quinlan-Waters M; Bohnsack JF; Cooper AM; Edelheit B; Twachtman-Bassett J; Lerman MA; Nanda K; Rabinovich CE; Lo MS; Pediatr Rheumatol Online J; 2024 Oct; 22(1):88. PubMed ID: 39375683 [TBL] [Abstract][Full Text] [Related]
10. The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. Beukelman T; Kimura Y; Ilowite NT; Mieszkalski K; Natter MD; Burrell G; Best B; Jones J; Schanberg LE; Pediatr Rheumatol Online J; 2017 Apr; 15(1):30. PubMed ID: 28416023 [TBL] [Abstract][Full Text] [Related]
11. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924 [TBL] [Abstract][Full Text] [Related]
12. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Shepherd J; Cooper K; Harris P; Picot J; Rose M Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404 [TBL] [Abstract][Full Text] [Related]
13. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S; Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312 [TBL] [Abstract][Full Text] [Related]
14. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Spencer CH; Rouster-Stevens K; Gewanter H; Syverson G; Modica R; Schmidt K; Emery H; Wallace C; Grevich S; Nanda K; Zhao YD; Shenoi S; Tarvin S; Hong S; Lindsley C; Weiss JE; Passo M; Ede K; Brown A; Ardalan K; Bernal W; Stoll ML; Lang B; Carrasco R; Agaiar C; Feller L; Bukulmez H; Vehe R; Kim H; Schmeling H; Gerstbacher D; Hoeltzel M; Eberhard B; Sundel R; Kim S; Huber AM; Patwardhan A; Pediatr Rheumatol Online J; 2017 Jun; 15(1):50. PubMed ID: 28610606 [TBL] [Abstract][Full Text] [Related]
15. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. Beukelman T; Ringold S; Davis TE; DeWitt EM; Pelajo CF; Weiss PF; Kimura Y; J Rheumatol; 2012 Sep; 39(9):1867-74. PubMed ID: 22859354 [TBL] [Abstract][Full Text] [Related]
16. Recent therapeutic advances in juvenile idiopathic arthritis. Giancane G; Alongi A; Rosina S; Tibaldi J; Consolaro A; Ravelli A Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):476-487. PubMed ID: 29773268 [TBL] [Abstract][Full Text] [Related]
17. Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance. Horton DB; Onel KB; Beukelman T; Ringold S J Rheumatol; 2017 Mar; 44(3):352-360. PubMed ID: 28148696 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Vastert SJ; de Jager W; Noordman BJ; Holzinger D; Kuis W; Prakken BJ; Wulffraat NM Arthritis Rheumatol; 2014 Apr; 66(4):1034-43. PubMed ID: 24757154 [TBL] [Abstract][Full Text] [Related]
19. Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra. Kearsley-Fleet L; Beresford MW; Davies R; De Cock D; Baildam E; Foster HE; Southwood TR; Thomson W; Hyrich KL Rheumatology (Oxford); 2019 Jan; 58(1):94-102. PubMed ID: 30137641 [TBL] [Abstract][Full Text] [Related]
20. Tocilizumab treatment in juvenile idiopathic arthritis patients: A single center experience. Demir S; Sönmez HE; Arslanoğlu-Aydın E; Özen S; Bilginer Y Turk J Pediatr; 2019; 61(2):180-185. PubMed ID: 31951328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]